XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Equity - USD ($)
Total
Total Caladrius Biosciences, Inc. Stockholders' Equity
Series B Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2016     10,000 8,205,790          
Beginning Balance at Dec. 31, 2016 $ 4,066,480 $ 4,883,909 $ 100 $ 8,206 $ 410,372,049 $ 0 $ (404,788,809) $ (707,637) $ (817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income 28,671,684 29,359,182         29,359,182   (687,498)
Unrealized loss on marketable securities (57,860) (57,860)       (57,860)      
Share-based compensation (in shares)       54,545          
Share-based compensation 2,350,652 2,350,652   $ 55 2,350,597        
Net proceeds from issuance of common stock (in shares)       648,432          
Net proceeds from issuance of common stock 3,278,632 3,278,632   $ 648 3,277,984        
Proceeds from option exercises (in shares)       3,835          
Proceeds from option exercises 13,576 13,576   $ 4 13,572        
Elimination of equity associated with PCT sale (3,686,526) 0             (3,686,526)
Conversion of redeemable securities 19,400,000 14,733,908     14,733,908       4,666,092
Change in ownership in subsidiary 0 (141,180)     (141,180)       141,180
Ending Balance (shares) at Jun. 30, 2017     10,000 8,912,602          
Ending Balance at Jun. 30, 2017 54,036,638 54,420,819 $ 100 $ 8,913 430,606,930 (57,860) (375,429,627) (707,637) (384,181)
Beginning Balance (shares) at Dec. 31, 2016     10,000 8,205,790          
Beginning Balance at Dec. 31, 2016 4,066,480 4,883,909 $ 100 $ 8,206 410,372,049 0 (404,788,809) (707,637) (817,429)
Ending Balance (shares) at Dec. 31, 2017     10,000 9,483,911          
Ending Balance at Dec. 31, 2017 50,189,786 50,508,069 $ 100 $ 9,484 433,044,209 (27,978) (381,810,109) (707,637) (318,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income (9,061,633) (9,058,950)         (9,058,950)   (2,683)
Unrealized loss on marketable securities (3,113) (3,113)       (3,113)      
Share-based compensation (in shares)       126,759          
Share-based compensation 1,712,064 1,712,064   $ 127 1,711,937        
Net proceeds from issuance of common stock (in shares)       50,070          
Net proceeds from issuance of common stock 287,554 287,554   $ 49 287,505        
Proceeds from option exercises (in shares)       74,621          
Proceeds from option exercises 341,893 341,893   $ 75 341,818        
Change in ownership in subsidiary 0 (47,547)     (47,547)       47,547
Ending Balance (shares) at Jun. 30, 2018     10,000 9,735,361          
Ending Balance at Jun. 30, 2018 $ 43,466,551 $ 43,739,970 $ 100 $ 9,735 $ 435,337,922 $ (31,091) $ (390,869,059) $ (707,637) $ (273,419)